Biohaven (Biohaven) Gross-Profit-to-Asset %

: 0.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Biohaven's annualized Gross Profit for the quarter that ended in Dec. 2023 was $0.00 Mil. Biohaven's average Total Assets over the quarter that ended in Dec. 2023 was $447.97 Mil. Therefore, Biohaven's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Biohaven Gross-Profit-to-Asset % Historical Data

The historical data trend for Biohaven's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Biohaven Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %								-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Biohaven's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biohaven Gross-Profit-to-Asset % Distribution

For the Biotechnology industry and Healthcare sector, Biohaven's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Biohaven's Gross-Profit-to-Asset % falls into.

Biohaven Gross-Profit-to-Asset % Calculation

Biohaven's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (661.783	+	513.212)	/ 2 )
	=	0	/	587.4975
	=	0.00 %

Biohaven's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (382.736	+	513.212)	/ 2 )
	=	0	/	447.974
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Biohaven Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Biohaven's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven (Biohaven) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 Church Street, New Haven, CT, USA, 06510

Website

https://www.biohavenpharma.com

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.

Executives

Irina Antonijevic	director	215 CHURCH STREET, NEW HAVEN CT 06510
John W Childs	director	111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric	director, officer: Chief Executive Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten	officer: Chief Financial Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark	officer: VP, Chief Accounting Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kimberly Gentile	officer: SVP, Clinical Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta	director	540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd.	10 percent owner	215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car	officer: Chief Scientific Officer	AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139